BR112017020484A2 - método para a fabricação de novo composto contendo nitrogênio ou sal do mesmo e intermediário de fabricação do novo composto contendo nitrogênio ou sal do mesmo - Google Patents
método para a fabricação de novo composto contendo nitrogênio ou sal do mesmo e intermediário de fabricação do novo composto contendo nitrogênio ou sal do mesmoInfo
- Publication number
- BR112017020484A2 BR112017020484A2 BR112017020484-3A BR112017020484A BR112017020484A2 BR 112017020484 A2 BR112017020484 A2 BR 112017020484A2 BR 112017020484 A BR112017020484 A BR 112017020484A BR 112017020484 A2 BR112017020484 A2 BR 112017020484A2
- Authority
- BR
- Brazil
- Prior art keywords
- salt
- containing compound
- manufacturing methods
- new nitrogen
- those producing
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 6
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- -1 nitrogen-containing compound Chemical class 0.000 title abstract 3
- 239000000543 intermediate Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000007112 amidation reaction Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/08—Copper compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
um método para fabricar eficazmente um composto contendo nitrogênio, que é usado para fabricar um agente de tratamento para doenças relacionadas à integrina, ou um sal do mesmo, e um intermediário de fabricação do composto ou um sal do mesmo são fornecidos. um método para fabricar um novo composto contendo nitrogênio ou um sal do mesmo inclui (1) uma etapa de obter um composto representado pela fórmula [10] ou um sal do mesmo através de uma reação de amidação; e (2) uma etapa de desproteger o composto representado pela fórmula [10] ou um sal do mesmo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-062306 | 2015-03-25 | ||
JP2015062306 | 2015-03-25 | ||
PCT/JP2016/059729 WO2016153054A1 (ja) | 2015-03-25 | 2016-03-25 | 新規な含窒素化合物またはその塩の製造方法およびそれらの製造中間体 |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112017020484A2 true BR112017020484A2 (pt) | 2018-07-03 |
BR112017020484B1 BR112017020484B1 (pt) | 2023-03-28 |
Family
ID=56977546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017020484-3A BR112017020484B1 (pt) | 2015-03-25 | 2016-03-25 | Métodos para fabricar um composto contendo nitrogênio ou sal do mesmo e um complexo metálico, compostos contendo nitrogênio, complexos dos ditos compostos e composições farmacêuticas compreendendo os ditos complexos |
Country Status (24)
Country | Link |
---|---|
US (3) | US20180008583A1 (pt) |
EP (3) | EP3275883B1 (pt) |
JP (1) | JP6411634B2 (pt) |
KR (1) | KR102029746B1 (pt) |
CN (2) | CN107428755B (pt) |
AU (4) | AU2016237099C1 (pt) |
BR (1) | BR112017020484B1 (pt) |
CA (1) | CA2980268C (pt) |
CO (1) | CO2017010806A2 (pt) |
CY (1) | CY1124387T1 (pt) |
DK (1) | DK3275883T3 (pt) |
ES (1) | ES2877707T3 (pt) |
HR (1) | HRP20211031T1 (pt) |
HU (1) | HUE059670T2 (pt) |
IL (4) | IL254532B (pt) |
LT (1) | LT3275883T (pt) |
MX (3) | MX2017012184A (pt) |
PL (1) | PL3275883T3 (pt) |
PT (1) | PT3275883T (pt) |
RS (1) | RS62165B1 (pt) |
RU (2) | RU2720989C2 (pt) |
SG (2) | SG11201707899SA (pt) |
SI (1) | SI3275883T1 (pt) |
WO (1) | WO2016153054A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3929196T (pt) | 2013-09-24 | 2023-09-11 | Fujifilm Corp | Composição farmacêutica de um novo composto contendo azoto ou seu sal, ou seu complexo de metal |
AU2018229275B2 (en) | 2017-02-28 | 2021-12-23 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
WO2018160522A1 (en) | 2017-02-28 | 2018-09-07 | Lazuli, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
TW202035400A (zh) | 2018-08-29 | 2020-10-01 | 美商莫菲克醫療股份有限公司 | 抑制αvβ6整合素 |
TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
CN113853220A (zh) * | 2019-03-11 | 2021-12-28 | 生物相容英国有限公司 | 用于中枢神经系统肿瘤治疗的放射性微球 |
GB202010626D0 (en) | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
JP2024500829A (ja) | 2020-12-21 | 2024-01-10 | アドヴァンスド アクセラレーター アプリケーションズ インターナショナル エセ.アー. | 治療診断剤として使用するための放射性標識α-Vβ-3及び/又はα-Vβ-5インテグリンアンタゴニスト |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5941386B2 (ja) | 1977-01-14 | 1984-10-06 | 株式会社紀文 | 高蛋白水産練製品様食品の製法 |
DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
CA2272565A1 (en) | 1996-11-27 | 1998-06-04 | Du Pont Pharmaceuticals Company | Integrin receptor antagonists |
DE69829996T2 (de) * | 1997-12-17 | 2006-02-23 | Merck & Co., Inc. (A New Jersey Corp.) | Integrin-rezeptor-antagonisten |
US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
JP2002532440A (ja) * | 1998-12-18 | 2002-10-02 | デュポン ファーマシューティカルズ カンパニー | ビトロネクチン受容体拮抗剤薬剤 |
EP1140203B1 (en) * | 1998-12-18 | 2007-05-23 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
AU780988B2 (en) | 2000-01-24 | 2005-04-28 | Merck & Co., Inc. | Alpha V integrin receptor antagonists |
EP1296678A2 (en) * | 2000-06-21 | 2003-04-02 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
KR100854424B1 (ko) | 2001-01-29 | 2008-08-27 | 3-디멘져널 파마슈티칼즈 인코오포레이티드 | 치환된 인돌 및 인테그린 길항제로서의 이들의 용도 |
KR101383655B1 (ko) | 2010-05-24 | 2014-04-10 | 주식회사 바이오이미징코리아 | 트리카르보닐 테크네슘-99m 또는 레늄-188 표지 고리 알지디 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 질환의 진단 또는 치료용 약학적 조성물 |
FR2968999B1 (fr) * | 2010-12-20 | 2013-01-04 | Guerbet Sa | Nanoemulsion de chelate pour irm |
FR2980364B1 (fr) * | 2011-09-26 | 2018-08-31 | Guerbet | Nanoemulsions et leur utilisation comme agents de contraste |
WO2013048996A1 (en) | 2011-09-30 | 2013-04-04 | Ge Healthcare Limited | Method for the purification of a peptide-based imaging agent precursor |
DK2840080T3 (da) * | 2012-04-17 | 2018-01-29 | Fujifilm Corp | Nitrogenholdig heterocyklisk forbindelse eller salt deraf |
FR3001154B1 (fr) * | 2013-01-23 | 2015-06-26 | Guerbet Sa | Magneto-emulsion vectorisee |
PT3929196T (pt) * | 2013-09-24 | 2023-09-11 | Fujifilm Corp | Composição farmacêutica de um novo composto contendo azoto ou seu sal, ou seu complexo de metal |
-
2016
- 2016-03-25 CN CN201680018240.1A patent/CN107428755B/zh active Active
- 2016-03-25 RS RS20210779A patent/RS62165B1/sr unknown
- 2016-03-25 SI SI201631232T patent/SI3275883T1/sl unknown
- 2016-03-25 CA CA2980268A patent/CA2980268C/en active Active
- 2016-03-25 BR BR112017020484-3A patent/BR112017020484B1/pt active IP Right Grant
- 2016-03-25 LT LTEPPCT/JP2016/059729T patent/LT3275883T/lt unknown
- 2016-03-25 WO PCT/JP2016/059729 patent/WO2016153054A1/ja active Application Filing
- 2016-03-25 PT PT167689579T patent/PT3275883T/pt unknown
- 2016-03-25 MX MX2017012184A patent/MX2017012184A/es unknown
- 2016-03-25 EP EP16768957.9A patent/EP3275883B1/en active Active
- 2016-03-25 EP EP22170836.5A patent/EP4059936A1/en active Pending
- 2016-03-25 SG SG11201707899SA patent/SG11201707899SA/en unknown
- 2016-03-25 HU HUE16768957A patent/HUE059670T2/hu unknown
- 2016-03-25 RU RU2017133107A patent/RU2720989C2/ru active
- 2016-03-25 DK DK16768957.9T patent/DK3275883T3/da active
- 2016-03-25 ES ES16768957T patent/ES2877707T3/es active Active
- 2016-03-25 SG SG10201902609TA patent/SG10201902609TA/en unknown
- 2016-03-25 PL PL16768957T patent/PL3275883T3/pl unknown
- 2016-03-25 KR KR1020177026236A patent/KR102029746B1/ko active IP Right Grant
- 2016-03-25 CN CN202010084360.XA patent/CN111171026B/zh active Active
- 2016-03-25 RU RU2020115068A patent/RU2767398C2/ru active
- 2016-03-25 JP JP2017508476A patent/JP6411634B2/ja active Active
- 2016-03-25 AU AU2016237099A patent/AU2016237099C1/en active Active
- 2016-03-25 EP EP21168086.3A patent/EP3872079A1/en not_active Withdrawn
-
2017
- 2017-09-17 IL IL254532A patent/IL254532B/en unknown
- 2017-09-22 US US15/712,815 patent/US20180008583A1/en not_active Abandoned
- 2017-09-25 MX MX2023005704A patent/MX2023005704A/es unknown
- 2017-09-25 MX MX2023005703A patent/MX2023005703A/es unknown
- 2017-10-24 CO CONC2017/0010806A patent/CO2017010806A2/es unknown
-
2019
- 2019-10-10 AU AU2019246859A patent/AU2019246859B2/en active Active
-
2020
- 2020-09-29 US US17/037,103 patent/US20210015802A1/en not_active Abandoned
- 2020-10-02 AU AU2020244578A patent/AU2020244578B2/en active Active
- 2020-10-02 AU AU2020244580A patent/AU2020244580B2/en active Active
-
2021
- 2021-05-18 IL IL283224A patent/IL283224B/en unknown
- 2021-05-19 IL IL283289A patent/IL283289B/en unknown
- 2021-05-19 IL IL283288A patent/IL283288B/en unknown
- 2021-06-29 HR HRP20211031TT patent/HRP20211031T1/hr unknown
- 2021-07-02 CY CY20211100591T patent/CY1124387T1/el unknown
-
2023
- 2023-02-21 US US18/112,423 patent/US20240108607A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017020484A2 (pt) | método para a fabricação de novo composto contendo nitrogênio ou sal do mesmo e intermediário de fabricação do novo composto contendo nitrogênio ou sal do mesmo | |
MX2019012942A (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak. | |
EA201890522A1 (ru) | Способ получения противогрибковых соединений | |
BR112016028773A2 (pt) | processos para preparação de compostos antivirais | |
BR112016024936A2 (pt) | moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes | |
MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
NZ721645A (en) | Compounds for use as gpr120 agonists | |
BR112015021386A2 (pt) | moduladores de ácido biciclo [2.2.2] gpr120 | |
EA201892515A1 (ru) | Стероидные 6,7-бета-эпоксиды в качестве интермедиатов | |
SG11201906688VA (en) | Novel ester compounds, method for the production thereof and use thereof | |
MA50169A (fr) | Procédé de production d'un électrocatalyseur | |
BR112016025024A2 (pt) | ?processo para preparar compostos ceto, e, uso de farnesil acetona? | |
MX369556B (es) | Procesos para la preparacion de derivados acidos de n-acetilgalactosamina (galnac). | |
EA201791645A1 (ru) | Новые соли и полиморфы scy-078 | |
BR112019001447A2 (pt) | método de produção para composto pirazol-amida | |
CL2019002636A1 (es) | Agente para el control de enfermedades en plantas. | |
BR112015024859A2 (pt) | processo e intermediários para a preparação de pregabalina | |
BR112016018594B8 (pt) | Método para produção do derivado de 2-aciliminopiridina | |
EA201990362A1 (ru) | Аналог вортиоксетина и его применение и получение | |
BR112018005930A2 (pt) | processo de preparação de compostos de indolina e um sal de indolina | |
BR112018003313A2 (pt) | novo derivado de catecol e composição farmacêutica compreendendo o mesmo | |
AR100095A1 (es) | Formas sólidas del ácido {[(2r,3s,4r,5s)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxi-benzoico | |
EA201691465A1 (ru) | Средство для лечения сердечно-сосудистых заболеваний | |
PH12018500176A1 (en) | Ameliorating agent for detrusor hyperactivity with impaired contractility | |
PH12017501560A1 (en) | Tetrahydropyranyl benzamide derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/03/2016, OBSERVADAS AS CONDICOES LEGAIS |